Molecular Screening & Influence of Cyp2C9*2 Variant with HHC in CVD Patients
DOI:
https://doi.org/10.46243/jst.2022.v7.i05.pp179-184Keywords:
CYP2C9*2 variant, Hyperhomocysteinemia, MTHFR, Cardiovascular diseaseAbstract
Cardiovascular diseases are the number one cause of death globally. An estimated 17.3 million people died from CVDs in 2008, representing 30% of all global deaths. Different risk factors contribute to the development of CVDs, mainly high blood pressure, obesity, diabetes mellitus and physical inactivity. One of the risk factor is the elevated level of homocysteine in blood. Homocysteine accumulates in the body due to the improper working of biochemical transformation process, usually due to deficiency of an enzyme, MTHFR, caused by the mutation. Hyperhomocysteinemia (HHC) is a condition that leads to the development of many cardiovascular diseases due to its clot causing ability. For the metabolism of the drugs taken against cardiovascular diseases, CYP family works. One member of CYP2C family, CYP2C9, is responsible for metabolizing various anticoagulants (such as Warfarin), that are prescribed for thrombophilic condition in HHC patients. In current study it is hypothesized that metabolism by CYP2C9*2 variant of CYP2C9, may have association with elevated homocysteine level in cardiovascular patients. To analyze the association of CYP2C9*2 variant of CYP2C9 family with Hyperhomocysteinemia, DNA was extracted from blood samples. PCR, RFLP, was performed on selected HHC samples with AvaII restriction enzyme and analyzed on gel documentation system. Among the three genotypes, CC, CT and TT, only CC and CT were found in this study. . Calculated P value was 0.924 that was greater than standard P value (P = 0.05), indicating no significant association between CYP2C9*2 and Hyperhomocysteinemia. BMI was found to be a major risk factor associated with CVD’s (Mean BMI = 36.39). Allelic frequency of C was 0.86% and frequency of T allele was 0.13% in HHC patients. On the basis of significant results, we may say that in our selected population, no association of CYP2C9*2 variant with elevated homocysteine level in patients with cardiovascular diseases be existent. For further studies, any other variant of CYP2C9 may be analyzed for an association with elevated homocysteine.
References
2. McKusick V. Homocystinuria due to deficiency of N (5,10)- methylene tetra hydro folate reductase activity. In: McKusick V, editor. Mendelian Inheritance in Man. Baltimore, MD: The Johns Hopkins University Press. 1992: 1447–1448
Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo ClinProc. 2008; 83:1203–1212
Boers GH. The case for mild hyperhomocysteinaemia as a risk factor. J Inherit Metab Dis 1997; 20:301–306
Austin RC, Lentz SR, Werstuck GH. Role of Hyperhomocystenemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 2004; 11(suppl 1):S56–S64
Ortiz de Montellano, PR. “Cytochrome P-450: Structure, Mechanism and Biochemistry,” Plenum, New York and London
Nebert DW, Nelson DR, Minor JC, Estabrook, RW, Feyereisen, R, Fuji-Kuriyama, Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, loper JC, Stato R, Waterman MR, Waxman DJ. The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 1991; 10:1-14
Nelson D.R., Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook, RW Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping,accession numbers and nomenclature. Pharmacogenetics 6. 1996; 1–42.7
Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics. 1995; 328–332
Morais SMF, Schweiki H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem. Biophys. Res. Commun. 1993; 194–201
Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994; 6:285–99
Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000; 10(3):187–216
Topic E, Stefanovic M, Samardzija M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. ClinChem Lab Med. 2004; 42(1):72–8
Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N. Substrate-dependent Functional Alternations of Seven CYP2C9 Variants Found in Japanese Subjects. Drug Metabolism and Disposition. 2009; 1895-903
Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a Noval Variant CYP2C9 Allele in Chinese. Pharmacogenetics. 2004; 465-469
Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of Polymorphisms in the Cytochrome P450 CYP2C9 with Warfarin Dose Requirement and Risk of Bleeding Complications. Lancet, Vol. 353, No. 9154, 1999, pp. 717-719. doi: 10.1016/s0140- 6736(98)04474-2
Schwarz UI, Clinical Relevance of Genetic Polymorphism in the Human CYP2C9 Gene. European Journal of Clinical Pharmacology. 2001; 277-280
Sistonen J, Fuselli S, Palo JU, Chauhan NH, Sajantila A, Pharmacogenetics variation at CYP2C9, CYP2C19, and CYP2D6 at global and micro geographic scales. Pharmacogenetics and genomics. 2009;19(2):170–9
Solus JF, Arietta BJ, Harris JR, Sexton DP, Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004;5(7):895–931
Lee CR, Goldstein JA, Pieper JA, Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12(3):251–63
Harmsze AM, Jochem W, Werkum V, Jurrie M, Berg T, Zwart B, Heleen J, Bouman NJ, Arnoud WJ, Hof V, Hendrik JT, Hackeng CM, Olaf H, Boer AD, Vera HM. CYP2C9*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case control study. European Heart Journal. 2010; 3046-3053
23.Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol. 2001; 277–280 Table 1: Mean values for the characteristics of HHC Table 2: Frequency of Parameters Table 3: Genotype Distribution of CC, CT and TT for CYP2C9*2 in HHC Patients and Controls Table 4: Chi-Square and P-value Calculated Using SPSS Version 16.0 Table 5: Mean BMI of HHC Patients in Effect of CYP2C9*2
